Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
The latest update is out from Biophytis ( (BPTSY) ).
Biophytis SA, a clinical-stage biotech focused on age-related diseases and longevity therapeutics, is advancing its lead candidate BIO101 for muscular and metabolic indications. The company operates from Paris with international subsidiaries and maintains listings in both Paris and on the U.S. OTC market, targeting the expanding global longevity and muscle health sectors.
From March 16 to 19, 2026, Biophytis and partner LynxKite Technologies participated in NVIDIA’s GTC 2026 conference, a major global forum for artificial intelligence and accelerated computing. Their joint presence, supported by Nebius AI Cloud, highlighted an AI-driven drug discovery platform for longevity, showcased BIO101 and the MAS receptor in a live demo, and included meetings with investors and industrial partners, underscoring Biophytis’ ambition to sit at the forefront of the $1.5 trillion longevity market.
The collaboration between Biophytis, LynxKite and Nebius combines aging biology expertise, graph-based AI and scalable GPU cloud infrastructure to accelerate modeling of biological targets. By engaging with technology leaders and potential collaborators at GTC, Biophytis signaled a strategic push to integrate advanced computational tools into its R&D, potentially strengthening its competitive position in AI-enabled longevity drug discovery.
The most recent analyst rating on (BPTSY) stock is a Hold with a $0.65 price target. To see the full list of analyst forecasts on Biophytis stock, see the BPTSY Stock Forecast page.
Spark’s Take on BPTSY Stock
According to Spark, TipRanks’ AI Analyst, BPTSY is a Neutral.
The score is primarily held down by weak financial performance (no revenue, ongoing cash burn, and negative equity), reinforced by bearish technicals with the stock trading below major moving averages. Valuation is also constrained by negative earnings and no dividend support, with only a minor offset from oversold momentum readings.
To see Spark’s full report on BPTSY stock, click here.
More about Biophytis
Biophytis SA is a clinical-stage biotechnology company developing drug candidates for age-related diseases, notably its lead small molecule BIO101 (20-hydroxyecdysone). BIO101 is Phase 3-ready for sarcopenia and Phase 2-ready for obesity, with the company headquartered in Paris and subsidiaries in Cambridge, Massachusetts, and Brazil, and its shares listed on Euronext Growth Paris and ADSs on the U.S. OTC market.
Average Trading Volume: 551
Technical Sentiment Signal: Sell
Current Market Cap: $2.65M
For detailed information about BPTSY stock, go to TipRanks’ Stock Analysis page.